Traders Buy High Volume of Call Options on Liquidia (NASDAQ:LQDA)

Liquidia Corporation (NASDAQ:LQDA) saw some unusual options trading activity on Wednesday. Traders bought 30,594 call options on the company. This represents an increase of 108% compared to the typical volume of 14,708 call options.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LQDA. Lifesci Capital upgraded shares of Liquidia from a “market perform” rating to an “outperform” rating and set a $59.00 target price for the company in a report on Wednesday. Weiss Ratings raised Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Zacks Research downgraded Liquidia from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 22nd. Needham & Company LLC reduced their price target on Liquidia from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of Liquidia in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $72.85.

Liquidia Price Performance

Shares of Liquidia stock opened at $34.78 on Friday. The business has a 50 day moving average of $61.21 and a 200 day moving average of $61.73. Liquidia has a 52 week low of $21.94 and a 52 week high of $93.61. The company has a market cap of $3.11 billion, a PE ratio of 24.77 and a beta of 0.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business’s revenue was up 1842.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.49) EPS. As a group, equities research analysts forecast that Liquidia will post 2.05 earnings per share for the current year.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Insider Activity at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 13,692 shares of the firm’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $389,948.16. Following the sale, the general counsel owned 602,841 shares of the company’s stock, valued at $17,168,911.68. This trade represents a 2.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Scott Moomaw sold 8,863 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $252,418.24. Following the completion of the transaction, the insider owned 181,487 shares in the company, valued at $5,168,749.76. The trade was a 4.66% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 745,194 shares of company stock worth $41,081,702 over the last ninety days. Insiders own 25.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Liquidia during the 2nd quarter valued at about $29,694,000. Eversept Partners LP boosted its stake in shares of Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after purchasing an additional 167,949 shares in the last quarter. Seven Fleet Capital Management LP increased its position in shares of Liquidia by 25.2% during the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after buying an additional 51,727 shares during the period. Finally, Pale Fire Capital SE increased its position in shares of Liquidia by 2.4% during the first quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after buying an additional 8,985 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).